Promoter holding
64.27%
NP
Natco Pharma Limited - Due diligence report
A 360° intelligence report on Natcopharma: trust score, financial health, credit view, compliance, directors, growth and distress signals - …
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Natcopharma — 360° Intelligence Report
Generated from MCA filings & public records73/100
Trust Score
Moderate
Natcopharma is assessed as Moderate with a Trust Score of 73/100. Natcopharma is an active public limited indian non-government company incorporated in 1981, operating in the Agriculture sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.
Report generated on 05 Jul 2026 from the latest processed filings. Natco Pharma Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
73/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
60/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
75/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
35/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
90/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 75/100 Low Risk
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (AA).
Charges position: 2 open (1,120.00 cr) · 56 satisfied (1,277.71 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| State Bank Of India | 6 | 48.0 cr |
| Others | 2 | 48.0 cr |
| Allahabad Bank | 13 | 48.0 cr |
| Export Import Bank Of India | 8 | 48.0 cr |
| Citi Bank N.A. | 3 | 48.0 cr |
| Axis Bank Limited | 2 | 48.0 cr |
Compliance Score: 60/100 Moderate
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2024).
- Litigation present in 3 court forum(s).
- Delayed payments to MSME suppliers disclosed (2 disclosure(s)).
- 25 active GST registration(s).
Legal cases on record (3)
05
Director Intelligence
Stability score: 35/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| LAKSHMINARAYANA BOLISETTY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAJEEV NANNAPANENI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VIJAYABHASKAR DRONADULA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VENKAT RAMESH CHEKURI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NITIN RAMESHWAR JAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| POTLURI PRASAD SIVARAMAKRISHNA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VENKAIAH CHOWDARY NANNAPANENI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| AGNIHOTRA DAKSHINA MURTY CHAVALI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KANTIPUDI SUMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| LINGARAO DONTHINENI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Veera Venkata Narasimha Appa Rao Sannidhanam | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 11 directors on the board.
- NITIN RAMESHWAR JAIN has DIN status "Deactivated due to non-filing of DIR-3 KYC".
- 4 director exits in 3 years - high churn.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
2 allotment(s) · 0 transfer(s)
Promoters hold a minority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Natco Lifesciences Philippines Inc. | Subsidiary Company | 74.00% |
| Natco Pharma (canada) Inc. | Subsidiary Company | 74.00% |
| Natco Pharma Asia Pte. Ltd. | Subsidiary Company | 74.00% |
| Natco Pharma Australia Pty Ltd. | Subsidiary Company | 74.00% |
| Natco Pharma Colombia S.a.s. | Subsidiary Company | 74.00% |
| Natco Pharma Inc. | Subsidiary Company | 74.00% |
| Natco Pharma Uk Limited | Subsidiary Company | 74.00% |
| Natco Pharma Usa Llc | Subsidiary Company | 74.00% |
| Natcofarma Do Brasil Ltda. | Subsidiary Company | 74.00% |
| Time Cap Overseas Limited | Subsidiary Company | 74.00% |
Key managerial personnel: RAJEEV NANNAPANENI (Whole-time director) · POTLURI PRASAD SIVARAMAKRISHNA (Whole-time director) · VENKAIAH CHOWDARY NANNAPANENI (Managing Director) · LINGARAO DONTHINENI (Whole-time director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 90 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +38% over 4 year(s).
Profit expanded 1.42 year-on-year.
Net margin improved to 2.1x.
EPFO headcount growing - hiring signal.
Operating for 44+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
3 director exits within 2 years.
2 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 5.40 Lakh.
3 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence70/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment76/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 2 open charge(s) of 1,120.00 cr already registered.
- Compliance gaps should be priced into terms.
Investor view86/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 4 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events18 Jul 2025
Charge created
State Bank Of India - 600.00 cr
30 Sep 2024
Last AGM held
Annual general meeting
29 Sep 2024
Director ceased
LAKSHMINARAYANA BOLISETTY
Director ceased
NITIN RAMESHWAR JAIN
Director ceased
KANTIPUDI SUMA
12 Aug 2024
Director appointed
LAKSHMINARAYANA BOLISETTY (Director)
Director appointed
NITIN RAMESHWAR JAIN (Director)
Director appointed
KANTIPUDI SUMA (Director)
01 Apr 2024
Director appointed
VIJAYABHASKAR DRONADULA (Director)
Director appointed
AGNIHOTRA DAKSHINA MURTY CHAVALI (Director)
Director ceased
SREERAMA MURTHY GUBBALA
31 Mar 2024
Latest balance sheet
Filed with ROC
09 Aug 2022
Director ceased
GANAPATI BHAT PAVAN
07 Apr 2022
Director ceased
ADINARAYANA MADINEEDI
01 Apr 2022
Director appointed
VENKAT RAMESH CHEKURI (Company Secretary)
10
Key Observations
Auto-generated from the data aboveRevenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Net worth is positive.
11 active director(s) / partner(s); review board churn before relying on management continuity.
25 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of AA from Icra.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a minority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
178 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| The Fertilisers And Chemicals Travancore | L24129KL1943GOI000371 | Ernakulam, Kerala, India |
| Godrejindustries | L24241MH1988PLC097781 | Mumbai, Maharashtra, India |
| Gland Pharma | L24239TG1978PLC002276 | Medchal Malkajgiri District Hyderabad, Telangana, India |
| Finolex Pipes | L40108PN1981PLC024153 | District Pune, Maharashtra, India |
| Ajanta Pharma | L24230MH1979PLC022059 | Mumbai, Maharashtra, India |
| Emcure | L24231PN1981PLC024251 | Pune City, Maharashtra, India |
| Bbil | U24119KA2016PLC093936 | Bengaluru, Karnataka, India |
| Himadri | L27106WB1987PLC042756 | Kolkata, West Bengal, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Natcopharma before audits and certifications: compliance score 60/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Natcopharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 75/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 90/100, margin trends, ownership structure and peer set for Natcopharma - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 73/100, distress signals and MSME payment-delay disclosures - know whether Natcopharma pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Natcopharma - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Natcopharma an active company?
Natcopharma has MCA status “Active” with a compliance score of 60/100 (Moderate).
Is Natcopharma financially healthy?
Natcopharma has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.
Should I do business with Natcopharma?
Its overall Trust Score is 73/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Natcopharma?
Promoters hold a minority stake - exact percentages are in the full report. 11 active director(s) are on record.
Does Natcopharma have loans or charges against its assets?
2 open charge(s) are registered against its assets, and 56 earlier charge(s) stand satisfied.
Is Natcopharma up to date with its ROC filings?
Balance sheet slightly behind (Mar 2024). Overall compliance score: 60/100 (Moderate).
Is it risky to lend to Natcopharma?
Its Credit Risk Score is 75/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
